echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > One in five patients has improved symptoms by more than 90%!

    One in five patients has improved symptoms by more than 90%!

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Dermavant Sciences announced the latest data analysis of tapinarof emulsion in two key phase 3 clinical trials for the treatment of patients with psoriasis.


    Psoriasis, also known as psoriasis, is a common chronic, autoimmune inflammatory skin disease.


    Tapinarof emulsion is a once-daily aromatic hydrocarbon receptor modulator (TAMA) being developed by Dermavant Sciences for the treatment of plaque psoriasis and atopic dermatitis.


    ▲The molecular structure of Tapinarof (photo source: Edgar181, Public domain, via Wikimedia Commons)

    The results of the trial showed that 18.


    "Our key Phase 3 clinical trial results add to the evidence for the effectiveness of tapinarof emulsion and will bring important changes to patients and the doctors who treat them.


    Reference materials:

    [1] Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.